Why the study?
Shortening DAPT is essential in high-bleeding-risk patients undergoing PCI, but the optimal antithrombotic approach in those requiring oral anticoagulation remains uncertain.
Does early transition to OAC monotherapy at 1 month provide comparable ischemic and bleeding outcomes to single antiplatelet therapy in high-bleeding-risk patients after PCI?
Does early transition to OAC monotherapy at 1 month provide comparable ischemic and bleeding outcomes to single antiplatelet therapy in high-bleeding-risk patients after PCI?
In high-bleeding-risk patients undergoing PCI, transitioning to OAC monotherapy at 1 month is a feasible strategy associated with low ischemic and bleeding risks comparable to single antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Supports OAC monotherapy transition at 1 month as feasible in high-bleeding-risk PCI; leaves open need for randomized confirmation.
BACKGROUND: In high-bleeding-risk (HBR) patients undergoing percutaneous coronary intervention (PCI), shortening dual antiplatelet therapy (DAPT) is essential, but the optimal approach in those requiring oral anticoagulation (OAC) is uncertain. We evaluated a 1-month dual antithrombotic regimen in HBR patients with and without OAC indication in a prespecified sub-analysis of the POEM trial. METHOD: POEM enrolled HBR patients treated with a bioresorbable polymer everolimus-eluting stent. Patients were stratified by OAC indication: the non-OAC group (n = 281) received 1-month DAPT followed by single antiplatelet therapy; the OAC group (n = 158) received 1-month OAC plus a P2Y12 inhibitor followed by OAC monotherapy. Time-to-event outcomes were analyzed using the log-rank test, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox regression models. The primary analysis was conducted according to the intention-to-treat principle. A per-protocol analysis, excluding patients with DAPT duration >1 month, was performed as a sensitivity analysis. RESULTS: At 1 year, the primary endpoint, a composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis, occurred in 6.1% of the non-OAC group versus 2.6% of the OAC group (HR 0.41, 95% CI 0.14-1.22; P = .097). Secondary ischemic outcomes were similar. BARC type 3-5 bleeding was infrequent (2.6% vs 1.3%; P = .369). The per-protocol analysis showed consistent results. CONCLUSIONS: In HBR patients after PCI, transition to OAC monotherapy at 1 month was associated with low ischemic and bleeding risks, comparable to single antiplatelet therapy. These findings support early OAC monotherapy as a feasible strategy warranting randomized investigation. TRIAL REGISTRATION: EudraCT Number: 2016-004510-99; clinicaltrials.gov: NCT03112707.
No takes yet. Share an insight, caveat, or question.
Pivato et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: